Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

NCT01836432 is registered in ClinicalTrials.gov with NewLink Genetics Corporation as lead sponsor.

NCT NCT01836432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01836432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Lead sponsor
NewLink Genetics Corporation
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2013
Completion date
March 24, 2017
Enrollment
302 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced malignant neoplasm, pancreatic cancer, pancreatic carcinoma non-resectable